Connect with us

World

Russia’s Vaccine Matters to the World

Published

on

Russia’s Vaccine

By Kester Kenn Klomegah

President Vladimir Putin has praised the entire healthcare system and particularly the hard-working team of scientists and specialists from different institutions for their efforts at research and creating a series of coronavirus vaccines for use against the coronavirus both at home and abroad.

Three vaccines already registered in Russia, two of them – Sputnik V and EpiVacCorona – are produced in large quantities by Russian pharmaceutical companies and are currently used for vaccination. It is additionally planned to roll out another one – CoviVac.

Despite the pandemic-related challenges, the domestic pharmaceutical companies, in conjunction with research institutes, have managed to accomplish a multitude of objectives in order to deploy new vaccine production sites in a short amount of time, Putin said during a videoconference meeting focused on increasing the manufacturing capacity of COVID-19 vaccines and the progress of vaccination in Russia.

Unreservedly made reference to staff qualities such as consistent and effective hard-work, truly selfless work and responsible attitude, and further urged them to continue making relentless efforts in stabilising the spread of the coronavirus infections and in protecting the life and health of millions of people in the country.

Putin further noted that the implementation of a wide range of preventive measures, including widespread vaccination, has played a significant role in normalising the epidemic situation.

Overall, 6.3 million Russians have taken the first part of the vaccine, of these 4.3 million have been vaccinated in full, that is, they have received both vaccine components.

“We can safely say, and the practical results indisputably corroborate, the fact that the Russian vaccines are absolutely safe and dependable. Our success is recognised abroad as well. The number of countries using the Sputnik V vaccine is expanding fast, more countries around the world are showing interest in our vaccine with 55 countries having authorised its use,” he told the meeting.

In addition, Russia now has a number of contracts with foreign manufacturers, – these are foreign manufacturers who will be producing our vaccine on their territory – have been signed for the number of doses needed to vaccinate 700 million people per year.

The latest, it has signed a contract with an Indian company for doses to vaccinate 100 million people. Indisputably, working with 55 countries means a total population of 1.4 billion. There are plans to expand the number of partner countries and that will reach an estimated 2.5 billion people.

While Russia and its pharmaceutical companies are considering the dynamics of the global market and the demand for Russian-made vaccines, and expanding their production capacities, it equally places emphasis on domestic needs, supplying and vaccinating Russian citizens with vaccines, is an absolute priority.

It is estimated that at least 60 per cent of all adults in the country must be vaccinated for complete stabilisation. This requires 69.8 million sets of vaccine doses. At any rate, there are more than 20 million Sputnik V doses, according to the Russian president, quoting his Prime Minister Mikhail Mishustin.

In his contribution at the meeting, Minister of Industry Denis Manturov informed that under the plan, 12.5 million sets of the vaccine must be produced in March. The planned figure for April is 17 million. It is planned to continue building up production so as to have over 80 million two-component doses by the first six months.

According to him, all these amounts will be primarily used to vaccinate Russian citizens. In order to meet the global demand for Russian vaccines, his ministry is working on scaling up the production of vaccines and on transferring technology abroad. It already has comprehensive agreements on this with manufacturers in 10 countries.

Healthcare Minister Mikhail Murashko informed the meeting about organisations that keep monitoring the virus’s mutations, including those in Russia. “We are analysing the efficiency of medicines for preventing the disease caused by various strains. This work is ongoing continuously and involves several agencies,” he said, and further mentioned the need to increase the speed of vaccination.

By the end of March, our healthcare facilities will receive over 6.5 million doses of Sputnik V. We expect that a total of some 30 million doses will be delivered in April and May. As of now, there are 4,500 stationary vaccination stations across Russia and plans to increase this figure, as well as over 1,000 mobile stations.

Participating in the meeting, Pharmstandard Chairman of the Board Viktor Kharitonin also discussed the production capability of the vaccine and pointed to the successful completion of the transfer of laboratory technology, scaled and fine-tuned the manufacturing technology abroad.

“It should be specifically pointed out that, thanks to our cooperation with the Russian Direct Investment Fund, we have started supplying the vaccine to foreign markets. We have already transferred the production technology to Kazakhstan and Belarus and continue working with other countries, including India and Italy. In Italy, Sputnik V was highly praised by both scientists and our colleagues from pharmaceutical companies,” added Kharitonin.

Taking his turn, Chairman of the Board of the R-Pharm Group Alexei Repik talked about efforts that are currently focused on the creation and manufacturing of new forms of the vaccine that will be easier to use and also to transport. He noted that it will increase the attractiveness of the vaccines on foreign markets, including countries with a hot climate: the Middle East, Africa and Latin America.

“Our factory is now producing the first registration batches of a promising lyophilic form of the vaccine created by our experts. It has proved stable at temperatures between +2 and +8 C. We are now studying its stability at room temperature. There are grounds to believe that we will succeed. This form will allow us to make the vaccine available in hard-to-reach regions of the country, which is especially important ahead of the spring and summer period,” informed Alexei Repik.

Director of the Gamaleya National Research Centre for Epidemiology and Microbiology Alexander Gintsburg also highlighted a few aspects of the vaccine production and about documents for registration. According to him, the Gamaleya Research Centre also addresses the problem of expanding the production of the Sputnik Light vaccine.

In addition, as the holder of the registration certificate, the Centre assumes all responsibility for quality control of this vaccine at all enterprises where it is manufactured in this country and abroad.

Moreover, the Centre is directly involved in launching contractual production that is mostly organised by the Russian Direct Investment Fund. The Centre has prepared the entire package of documents for registering the Sputnik Light vaccine in 55 countries. Considering that each country has its own regulatory system, this is not a fixed package of documents that will apply everywhere, therefore it has to adapt it to every country’s regulatory system.

He further spoke about The Lancet, a highly prestigious and popular medical journal, that published two articles on the results of scientific data and clinical trials. This provides important scientific evidence proving the vaccine’s efficacy, this has completely eliminated the Western academic community’ scepticism regarding the vaccines’ quality and efficacy.

Alexander Gintsburg explained a little about children’s vaccination. According to him, children must be divided into several age groups. Russian experts and specialists in paediatric immunology are working in this direction. He said that a vaccine has been developed, patented, and are currently launching clinical trials of Sputnik V’s intranasal form. This is a very gentle and patient-friendly form of vaccination for children, especially little children, who can be traumatised when they see a syringe or when possible side effects arise. The first experiments show that the intranasal form is completely free from any side effects.

CEO of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev stressed patent protection and protecting intellectual rights for Russian made vaccines and other medical products. “Our patent protection is very strong. We submitted applications early on, much earlier than other countries, and thus got a headstart. Accordingly, the Gamaleya Institute owns the innovations that are available even at these foreign sites, which include over 20 partner companies in 10 countries,” he told the meeting.

On foreign cooperation, “Mr President, I would like to thank you, because it was your idea to build production partnerships with various countries, and 20 manufacturers from over 10 countries responded. For them, it’s about vaccine safety and independence, and Russia was the only country to have come up with this offer. Thank you very much. They are very grateful to you for this,” Kirill Dmitriev said in appreciation.

Director-General of the Vektor State Research Centre of Virology and Biotechnology Rinat Maksyutov discussed various research operations. Vektor is the only WHO COVID-19 reference laboratory in Russia. It not only conducts the entire range of viral studies of the novel coronavirus but is also monitoring its genetic mutations across the country on a regular basis.

“By now, we have found over 5,300 genetic variations across the genome. In the overwhelming number of cases, the replacement does not change the epidemiological characteristics of the virus. At the same time, we have also found over 50 variations of the British strain, three cases of the South African strain and over 20 unique variations of the virus that must be thoroughly studied,” he said.

According to Rinat Maksyutov, the Research Centre Vektor is studying these variations of the virus in accordance with a special algorithm. “We are studying the virus’s stability on various surfaces; we are also using unique equipment, which has no analogues throughout the world, to study the ability of the virus to be transmitted between living organisms. We have found that the British strain of the novel coronavirus can be effectively neutralised by serum taken from those who had COVID and those vaccinated with Sputnik V or EpiVacCorona,” he told the meeting.

Director-General of the Chumakov Federal Scientific Centre for the Research and Development of Immune and Biological Products (Russian Academy of Sciences) Aidar Ishmukhametov spoke about their engagement and involvement in research and production of medical products, tracing its roots to the Soviet Union.

The Chumakov Centre is one of the oldest facilities in the Russian Federation and the oldest vaccine developer in Russia. That in the 1960s, this centre’s achievements helped the country deal with polio. The centre back then developed a unique vaccine that supplied to the entire world, including the United States, Europe, Japan and many other countries. In fact, now this facility, the Institute of Poliomyelitis, is well-known around the world.

It is continuing this tradition. As of today, it has developed and produced five vaccines, including for tick-borne encephalitis, rabies and the yellow fever vaccine that is supplied to almost 50 countries, which is perhaps Russia’s biggest export in the pharmaceutical industry.

This type of organisation that has a research and development facility at its core that can outline the task and release a certain number of batches of the vaccine consisting of tens of millions [of doses], on one hand, and well-coordinated work with research institutes and the search for partners, on the other hand, is a very efficient model.

“We did not intend to work exclusively on the coronavirus vaccine. It was important to us to maintain the same production volume and supply vaccines according to the national vaccination calendar as well as deliver on the exports. So we needed to fit this new objective into our existing model. We inherited this research and development facility from the Soviet Union where it was a leader in this industry, and we are developing it,” he underlined the importance of his institution at the meeting.

CEO of the National Immunobiological Company, Rostec State Corporation, Andrei Zagorsky, however, noted that vaccine production is growing steadily. He highlighted the question of warehousing (storage), freezer facility and shipping to the regions. This is carried out in close cooperation with the manufacturing sites, as well as cargo recipients in the regions. These tasks are fulfilled on schedule, he said.

“We monitor the entire production process, especially the temperature, all the way from production, transport, acceptance to a warehouse, storage at the warehouse, to shipment to a recipient region. All products are transported in thermal containers, which can keep temperatures at 18 degrees below zero Celsius for about five days,” he added, speaking at the meeting.

Deputy Prime Minister Tatyana Golikova concluded with high appreciation. The meeting ended with a clear understanding of what direction should be moving to overcome the coronavirus pandemic and at the same time, extend assistance to foreign countries that are in need.

She, however, reiterated that, in a fairly short time, despite the difficulties and amid the challenging pandemic of 2020, all her colleagues have indeed accomplished something that seemed almost impossible, worked 24/7 and made Russia the leader in the production and use of vaccines, primarily, for the public in Russia.

Kester Kenn Klomegah is a versatile researcher and a passionate contributor. Most of his well-resourced articles are reprinted elsewhere in a number of reputable foreign media.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

World

Abebe Selassie to Retire as Director of African Department at IMF

Published

on

Abebe Aemro Selassie

By Kestér Kenn Klomegâh

The International Monetary Fund (IMF) has announced the retirement of its director of the African department, Abebe Aemro Selassie, on May 1, 2026. Since his appointment in 2016, Abebe Selassie has served in this position for a decade. During his tenure, IMF added a 25th chair to its Executive Board, increasing the voice of sub-Saharan Africa.

As a director for Africa, he has overseen the IMF’s engagement with 45 countries across sub-Saharan Africa. Abebe and his team work closely with the region’s leaders and policymakers to improve economic and development outcomes. This includes oversight of the IMF’s intensified engagement with the region in recent years, including some $60 billion in financial support the institution has provided to countries since 2020. Reports indicated that under his leadership, his department generally reinforces the organization’s role as a trusted partner to many African countries.

Abebe Selassie has worked with both the regional economic blocs and the African Union (AU) as well as individual African states. The key focus has been the strategic articulation of Africa’s development priorities in reshaping economic governance, mobilizing sustainable investments, and addressing systemic financial challenges.

It is important noting that the IMF has funded diverse infrastructure projects that facilitated either export-led growth or import substitution industrialization models of development. Further to that, African states have also made numerous loans and benefited from much-needed debt relief.

Summarizing the IMF’s key focus areas, among others, for Africa: (i) reforming the global financial architecture in an effort to improve the structure, institutions, rules, and processes that govern international finance in order to make the global economy more stable, equitable, and resilient.

Concessional financing to counter rising borrowing costs, with Africa paying up to 5 times more in interest than advanced economies (AfDB, 2023). Fair representation, pushing for IMF quota reforms to reflect Africa’s $3.4 trillion collective GDP—yet the continent holds less than 5% of voting shares in Bretton Woods institutions.

(ii) Unlocking Investments for Jobs and Sustainable Growth. With Africa’s working-age population set to double to 1 billion by 2050, the African states spotlight: The African Continental Free Trade Area (AfCFTA), projected to boost intra-African trade by 52% and create 30 million jobs by 2035 (World Bank, 2024).  Infrastructure partnerships, targeting sectors such as renewable energy, where Africa receives only 2% of global clean energy investments despite its vast solar and wind potential (IEA, 2024).

(iii) Climate Finance and Debt Relief for Resilience: Africa contributes less than 4% of global emissions but bears the brunt of climate shocks, losing 5–15% of GDP per capita to climate-related disasters annually (African Development Bank, 2024). These are strictly in alignment with Agenda 2063’s aspirations for inclusive growth, maximizing multilateral cooperation and enhancing global engagement with the continent.

“I am deeply grateful for Abe’s visionary leadership, dedication to the Fund’s mission, and unwavering commitment to the members in the region,” Ms. Kristalina Georgieva, Managing Director of the International Monetary Fund (IMF). “The legacy he leaves on the Fund’s work in Africa is one of alignment with the aspirations of people, especially the youth, for good governance, strong economies and lasting prosperity. His trusted advice has been invaluable to me personally, and his leadership has strengthened our mission.”

“A national of Ethiopia, Selassie first joined the IMF in 1994. Over his remarkable 32-year career, he held senior positions including Deputy Director in AFR, Mission Chief for Portugal and South Africa, Division Chief of the Regional Studies Division, and Senior Resident Representative in Uganda. Earlier, he contributed to programs in Turkey, Thailand, Romania, and Estonia, and worked on policy, operational review, and economic research.”

Under his ten-year leadership and as director of the African Department (AFR), Abebe Selassie helped to reinforce the Fund’s role as a trusted partner with sub-Saharan African members. The International Monetary Fund (IMF) is an international organization that promotes global economic growth and financial stability, encourages international trade, and reduces poverty.

Continue Reading

World

Africa Squeezed between Import Substitution and Dependency Syndrome

Published

on

Dependency Syndrome

By Kestér Kenn  Klomegâh

Squeezed between import substitution and dependency syndrome, a condition characterized by a set of associated economic symptoms—that is rules and regulations—majority of African countries are shifting from United States and Europe to an incoherent alternative bilateral partnerships with Russia, China and the Global South.

By forging new partnerships, for instance with Russia, these African countries rather create conspicuous economic dependency at the expense of strengthening their own local production, attainable by supporting local farmers under state budget. Import-centric partnership ties and lack of diversification make these African countries committed to import-dependent structures. It invariably compounds domestic production challenges. Needless to say that Africa has huge arable land and human resources to ensure food security.

A classical example that readily comes to mind is Ghana, and other West African countries. With rapidly accelerating economic policy, Ghana’s President John Dramani Mahama ordered the suspension of U.S. chicken and agricultural products, reaffirming swift measures for transforming local agriculture considered as grounds for ensuring sustainable food security and economic growth and, simultaneously, for driving job creation.

President John Dramani Mahama, in early December 2025, while observing Agricultural Day, urged Ghanaians to take up farming, highlighting the guarantee and state support needed for affordable credit and modern tools to boost food security. According to Mahama, Ghana spends $3bn yearly on basic food imports from abroad.

The government decision highlights the importance of leveraging unto local agriculture technology and innovation. Creating opportunities to unlock the full potential of depending on available resources within the new transformative policy strategy which aims at boosting local productivity. President John Dramani Mahama’s special initiatives are the 24-Hour Economy and the Big Push Agenda. One of the pillars focuses on Grow 24 – modernising agriculture.

Despite remarkable commendations for new set of economic recovery, Ghana’s demand for agricultural products is still high, and this time making a smooth shift to Russia whose poultry meat and wheat currently became the main driver of exports to African countries. And Ghana, noticeably, accepts large quantity (tonnes) of poultry from Russia’s Rostov region into the country, according to several media reports. The supplies include grains, but also vegetable oils, meat and dairy products, fish and finished food products have significant potential for Africa.

The Agriculture Ministry’s Agroexport Department acknowledges Russia exports chicken to Ghana, with Ghanaian importers sourcing Russian poultry products, especially frozen cuts, to meet significant local demand that far outstrips domestic production, even after Ghana lifted a temporary 2020 avian flu-related ban on Russian poultry.

Moreover, monitoring and basic research indicated Russian producers are actively increasing poultry exports to various African countries, thus boosting trade, although Ghana still struggles to balance imports with local industry needs.

A few details indicate the following:

Trade Resumed: Ghana has lifted its ban on Russian poultry imports since April 2021, allowing poultry trade to resume. Russian regions have, thus far, consistently exported these poultry meat and products into the country under regulatory but flexible import rules on a negotiated bilateral agreement.

Significant Market: In any case, Ghana is a key African market for Russian poultry, with exports seeing substantial growth in recent years, alongside Angola, Benin, Cote d’Voire, Nigeria and Sierra Leone.

Demand-Driven: Ghana’s large gap between domestic poultry production and national demand necessitates significant imports, creating opportunities for foreign suppliers like Russia.

Major Exporters: Russia poultry companies are focused on increasing generally their African exports, with Ghana being a major destination. The basic question: to remain as import dependency or strive at attaining food sufficiency?

Product Focus: Exports typically include frozen chicken cuts (legs and meat) very vital for supplementing local supply. But as the geopolitical dynamics shift, Ghana and other importing African countries have to review partnerships, particularly with Russia.

Despite the fact that challenges persist, Russia strongly remains as a notable supplier to Ghana, even under the supervision of John Mahama’s administration, dealing as a friendly ally, both have the vision for multipolar trade architecture, ultimately fulfilling a critical role in meeting majority of African countries’ large consumer demand for poultry products, and with Russia’s trade actively expanding and Ghana’s preparedness to spend on such imports from the state budget.

Following two high-profile Russia–Africa summits, cooperation in the area of food security emerged as a key theme. Moscow pledged to boost agricultural exports to the continent—especially grain, poultry, and fertilisers—while African leaders welcomed the prospect of improved food supplies.

Nevertheless, do these African governments think of prioritising agricultural self-sufficiency. At a May 2025 meeting in St. Petersburg, Russia’s Economic Development Minister, Maxim Reshetnikov, underlined the fact that more than 40 Russian companies were keen to export animal products and agricultural goods to the African region.

Russia, eager to expand its economic footprint, sees large-scale agricultural exports as a key revenue generator. Estimates suggest the Russian government could earn over $15 billion annually from these agricultural exports to African continent.

Head of the Agroexport Federal Center, Ilya Ilyushin, speaking at the round table “Russia-Africa: A Strategic Partnership in Agriculture to Ensure Food Security,” which was held as part of the international conference on ensuring the food sovereignty of African countries in Addis Ababa (Ethiopia) on Nov. 21, 2025, said: “We see significant potential in expanding supplies of Russian agricultural products to Africa.”

Ilya Ilyushin, however, mentioned that the Agriculture Ministry’s Agroexport Department, and the Union of Grain Exporters and Producers, exported over 32,000 tonnes of wheat and barley to Egypt totaling nearly $8 million during the first half of 2025, Kenya totaling over $119 million.

Interfax media reports referred to African countries whose markets are of interest for Russian producers and exporters. Despite existing difficulties, supplies of livestock products are also growing, this includes poultry meat, Ilyushin said. Exports of agricultural products from Russia to African countries have more than doubled, and third quarter of 2025 reached almost $7 billion.

The key buyers of Russian grain on the continent are Egypt, Algeria, Kenya, Libya, Tunisia, Nigeria, Morocco, South Africa, Tanzania and Sudan, he said. According to him, Russia needs to expand the geography of supplies, increasing exports to other regions of the continent, increase supplies in West Africa to Benin, Cameroon, Ghana, Liberia and the French-speaking Sahelian States.

Nevertheless, Russian exporters have nothing to complain. Africa’s dependency dilemma still persists. Therefore, Russia to continue expanding food exports to Africa explicitly reflects a calculated economic and geopolitical strategy. In the end of the analysis, the debate plays out prominently and the primary message: Africa cannot and must not afford to sacrifice food sovereignty for colourful symbolism and geopolitical solidarity.

With the above analysis, Russian exporters show readiness to explore and shape actionable strategies for harnessing Africa’s consumer market, including that of Ghana, and further to strengthen economic and trade cooperation and support its dynamic vision for sustainable development in the context of multipolar friendship and solidarity.

Continue Reading

World

Coup Leader Mamady Doumbouya Wins Guinea’s 2025 Presidential Election

Published

on

Mamady Doumbouya

By Adedapo Adesanya

Guinea’s military leader Mamady Doumbouya will fully transition to its democratic president after he was elected president of the West African nation.

The former special forces commander seized power in 2021, toppling then-President Alpha Conde, who had been in office since 2010.

Mr Doumbouya reportedly won 86.72 per cent of the election held on December 28, an absolute majority that allows him to avoid a runoff. He will hold the forte for the next seven years as law permits.

The Supreme Court has eight days to validate the results in the event of any challenge. However, this may not be so as ousted Conde and Mr Cellou Dalein Diallo, Guinea’s longtime opposition leader, are in exile.

The election saw Doumbouya face off a fragmented opposition of eight challengers.

One of the opposition candidates, Mr Faya Lansana Millimono claimed the election was marred by “systematic fraudulent practices” and that observers were prevented from monitoring the voting and counting processes.

Guinea is the world leader in bauxite and holds a very large gold reserve. The country is preparing to occupy a leading position in iron ore with the launch of the Simandou project in November, expected to become the world’s largest iron mine.

Mr Doumbouya has claimed credit for pushing the project forward and ensuring Guinea benefits from its output. He has also revoked the licence of Emirates Global Aluminium’s subsidiary Guinea Alumina Corporation following a refinery dispute, transferring the unit’s assets to a state-owned firm.

In September, rating agency, Standard & Poor’s (S&P), assigned an inaugural rating of “B+” with a “Stable” outlook to the Republic of Guinea.

This decision reflects the strength of the country’s economic fundamentals, strong growth prospects driven by the integrated mining and infrastructure Simandou project, and the rigor in public financial management.

As a result, Guinea is now above the continental average and makes it the third best-rated economy in West Africa.

According to S&P, between 2026 and 2028, Guinea could experience GDP growth of nearly 10 per cent per year, far exceeding the regional average.

Continue Reading

Trending